

What is claimed is:

- 1 1. An enveloped pharmaceutical composition comprising:
  - 2 a first active available for immediate release; and
  - 3 a second active for extended release selected from the group consisting of a
  - 4 decongestant, an antihistamine, an expectorant, an antitussive and mixtures thereof,
  - 5 wherein the first and the second active are disposed on separate carriers.
- 1 2. The composition of claim 1, wherein the first and second actives are enveloped in
- 2 a single dose.
- 1 3. The composition of claim 1, wherein the first and second actives are enveloped
- 2 into a single dose.
- 1 4. The composition of claim 1, wherein the first and second actives are packed into a
- 2 capsule, caplet, softgel, gelcap, suppository, film, granule, gum, insert, pastille, pellet,
- 3 troche, lozenge, disk, poultice or wafer.
- 1 5. The composition of claim 1, wherein over 80% of the first active is released
- 2 within about 60 minutes.
- 1 6. The composition of claim 1, wherein immediate release is defined further as
- 2 comprising release of over 90% of the first active within about 90 minutes.
- 1 7. The composition of claim 1, wherein extended release is defined further as
- 2 comprising release of over 80% of the second active within about 60 minutes to about 8
- 3 hours.
- 1 8. The composition of claim 1, wherein extended release is defined further as
- 2 comprising release of over 90% of the second active within about 90 minutes to about 6
- 3 hours.
- 1 9. The composition of claim 1, wherein the first active comprises gauifenesin.
- 1 10. The composition of claim 1, wherein the first active comprises gauifenesin DC in
- 2 a powder form.

- 1 11. The composition of claim 1, wherein the first active comprises 211 mg of 95%
- 2 gauifenesin.
- 1 12. The composition of claim 1, wherein the second active comprises a nasal
- 2 decongestant.
- 1 13. The composition of claim 1, wherein the second active comprises phenylephrine.
- 1 14. The composition of claim 1, wherein the second active comprises phenylephrine
- 2 as a sustained release bead.
- 1 15. The composition of claim 1, wherein the second active comprises phenylephrine
- 2 as a layered sustained release bead.
- 1 16. The composition of claim 1, wherein the second active comprises three or more
- 2 layers of phenylephrine on a bead.
- 1 17. The composition of claim 1, wherein the first active is superposed on the second
- 2 active.
- 1 18. The composition of claim 1, comprising further one or more inactives.
- 1 19. The composition of claim 1, wherein the first active for immediate release
- 2 comprises a powder form and the second active comprises a beaded form.
- 1 20. An enveloped pharmaceutical composition comprising:
  - 2 a first active available for immediate release; and
  - 3 a second active available for extended release, wherein the first active effects a
  - 4 physiological result that improves the physiological action of the second active upon
  - 5 extended release.
- 1 21. The composition of claim 20, wherein the first and second actives are enveloped
- 2 in a single dose.
- 1 22. The composition of claim 20, wherein the first and second actives are enveloped
- 2 into a single dose.

- 1 23. The composition of claim 20, wherein the first and second actives are packed into
- 2 a capsule, caplet, softgel, gelcap, suppository, film, granule, gum, insert, pastille, pellet,
- 3 troche, lozenge, disk, poultice or wafer.
- 1 24. The composition of claim 20, wherein over 80% of the first active is released
- 2 within about 60 minutes.
- 1 25. The composition of claim 20, wherein immediate release is defined further as
- 2 comprising release of over 90% of the first active within about 90 minutes.
- 1 26. The composition of claim 20, wherein extended release is defined further as
- 2 comprising release of over 80% of the second active within about 60 minutes to about 8
- 3 hours.
- 1 27. The composition of claim 20, wherein extended release is defined further as
- 2 comprising release of over 90% of the second active within about 90 minutes to about 6
- 3 hours.
- 1 28. The composition of claim 20, wherein the second active for extended release is
- 2 selected from the group consisting of a decongestant, an antihistamine, an expectorant, an
- 3 antitussive and mixtures thereof.
- 1 29. The composition of claim 20, wherein the first active comprises gauifenesin.
- 1 30. The composition of claim 20, wherein the first active comprises Gauifenesin DC
- 2 in a powder form.
- 1 31. The composition of claim 20, wherein the first active comprises 211 mg of 95%
- 2 gauifenesin.
- 1 32. The composition of claim 20, wherein the second active comprises a nasal
- 2 decongestant.
- 1 33. The composition of claim 20, wherein the second active comprises phenylephrine.
- 1 34. The composition of claim 20, wherein the second active comprises phenylephrine
- 2 as a sustained release bead.

1 35. The composition of claim 20, wherein the second active comprises phenylephrine  
2 as a layered sustained release bead.

1 36. The composition of claim 20, wherein the second active comprises three or more  
2 layers of phenylephrine on a bead.

1 37. The composition of claim 20, wherein the first active is superposed on the second  
2 active.

1 38. The composition of claim 20, comprising further one or more inactives.

1 39. The composition of claim 20, wherein the first active for immediate release  
2 comprises a powder form and the second active comprises a beaded form.

1 40. An enveloped pharmaceutical composition comprising:

2 a first active packaged so that over 90 % of the first active is released within about  
3 90 minutes; and

4 a second active for extended release selected from the group consisting of a decongestant,  
5 an antihistamine, an expectorant, an antitussive and mixtures thereof, wherein over 90%  
6 of the second active is released between about 1 and 6 hours.

1 41. The composition of claim 40, wherein the first and the second actives are  
2 disposed on separate carriers.

1 42. The composition of claim 40, wherein the first and second actives are enveloped  
2 in a single dose.

1 43. The composition of claim 40, wherein the first and second actives are enveloped  
2 into a single dose.

1 44. The composition of claim 40, wherein the first and second actives are packed into  
2 a capsule, caplet, softgel, gelcap, suppository, film, granule, gum, insert, pastille, pellet,  
3 troche, lozenge, disk, poultice or wafer.

1 45. The composition of claim 40, wherein over 80% of the first active is released  
2 within about 60 minutes.

1 46. The composition of claim 40, wherein immediate release is defined further as  
2 comprising release of over 90% of the first active within about 60 minutes.

1 47. The composition of claim 40, wherein extended release is defined further as  
2 comprising release of over 80% of the second active within about 60 minutes to about 8  
3 hours.

1 48. The composition of claim 40, wherein extended release is defined further as  
2 comprising release of over 90% of the second active within about 90 minutes to about 6  
3 hours.

1 49. The composition of claim 40, wherein the first active comprises gauifenesin.

1 50. The composition of claim 40, wherein the first active comprises gauifenesin in a  
2 powder form.

1 51. The composition of claim 40, wherein the first active comprises 211 mg of 95%  
2 gauifenesin.

1 52. The composition of claim 40, wherein the second active comprises a nasal  
2 decongestant.

1 53. The composition of claim 40, wherein the second active comprises phenylephrine.

1 54. The composition of claim 40, wherein the second active comprises phenylephrine  
2 as a sustained release bead.

1 55. The composition of claim 40, wherein the second active comprises phenylephrine  
2 as a layered sustained release bead.

1 56. The composition of claim 40, wherein the second active comprises three or more  
2 layers of phenylephrine on a bead.

1 57. The composition of claim 40, wherein the first active is superposed on the second  
2 active.

1 58. The composition of claim 40, comprising further one or more inactives.

1 59. The composition of claim 40, wherein the first active for immediate release  
2 comprises a powder form and the second active comprises a beaded form.

1 60. An enveloped pharmaceutical composition comprising:

2 a first active available for immediate effervescent release; and

3 a second active for extended release in a mini-tab selected from the group  
4 consisting of a decongestant, an antihistamine, an expectorant, an antitussive and  
5 mixtures thereof.

1 61. An enveloped pharmaceutical composition comprising:

2 a first active available for immediate release; and

3 a second active for extended release selected from the group consisting of a  
4 decongestant, an antihistamine, an expectorant, an antitussive and mixtures thereof  
5 wherein the first and second actives are different.

1 62. An liquid pharmaceutical composition comprising:

2 a first active available for immediate release; and

3 a second active coated on or about one or more suspended beads for extended  
4 release selected from the group consisting of a decongestant, an antihistamine, an  
5 expectorant, an antitussive and mixtures thereof, wherein the first active effects a  
6 physiological result that improves the physiological action of the second active upon  
7 extended release.

1 63. The liquid pharmaceutical composition of claim 62, wherein the first and second  
2 active are made available in a solution, suspension, cream, ointment, lotion, enema,  
3 elixir, syrup, emulsion, gum, insert, jelly, foam, paste, pastille, spray, magma or poultice.

1 62. A method of loading one or more actives on a bead for extended release  
2 comprising:

3 adding a first active onto one or more beads with an adhesive and a sustained  
4 release coating; and

5 adding a extended release coating prior to or in combination with a second active.

1 63. The method of claim 62, wherein the adhesive comprises a pharmaceutical glaze.

1 64. The method of claim 62, wherein the adhesive is a sustained release coating that  
2 is added prior to the addition of the first active.

1 65. The method of claim 62, wherein the adhesive is a sustained release coating that  
2 is added concurrent with the addition of the first active.

1 66. The method of claim 62, wherein the adhesive is a sustained release coating is  
2 about or after the addition of the first active.

1 67. The method of claim 62, wherein the adhesive is a sustained release coating is  
2 mixed with the first active, and the mixture is added onto one or more beads.

1 68. The method of claim 67, wherein the bead comprises a portion of a mini-tab.

1 69. The method of claim 62, further comprising the step of adding an erosion matrix.

1 70. The method of claim 62, further comprising the step of adding one or more  
2 inactives.

1 71. A method of loading an active into a mini-tab to be encapsulated for extended  
2 release, using an erosion matrix.

1 72. A method of providing a dual-release formulation comprising:  
2 a first active in a powered form and a second active in an extended release form,  
3 wherein the first and second actives are loaded into a capsule.

1 73. A method of loading an active on a bead comprising:  
2 adding the active onto one or more beads with a pharmaceutical glaze;  
3 curing the active and the glaze for between about 3 to 6 hours prior to adding a  
4 sustained release coating; and  
5 repeating the steps of adding active and curing the active at least two more times.

1 74. The method of claim 73, wherein the active comprises a decongestant.

1 75. The method of claim 73, wherein the active comprises phenylephrine.

1 76. A method of providing a dual-release formulation comprising:

2       providing a first active comprising an expectorant packed for immediate release in

3 a powder form;

4       providing a second active comprising a nasal decongestant packed for extended

5 release on a bead, and

6       enveloping the first and the second actives, wherein the first active provides

7 productive coughs in the short-term and the second active provides long acting

8 decongestant activity.

1 77. A method of providing a dual-release formulation comprising:

2       providing a first active comprising an expectorant packed for immediate release in

3 a powder form;

4       providing a second active comprising a nasal decongestant packed for extended

5 release on a bead, and

6       encapsulating the first and the second actives, wherein the first active provides

7 productive coughs in the short-term and the second active provides long acting

8 decongestant activity.

1 78. A method of providing a dual-release formulation comprising:

2       providing a first active comprising an expectorant packed for immediate release in

3 a powder form;

4       providing a second active comprising a nasal decongestant packed for extended

5 release on a bead, and

6       suspending the first and the second actives in a liquid medium, wherein the first

7 active provides productive coughs in the short-term and the second active provides long

8 acting decongestant activity.